Last updated: October 5, 2026
MOBAN is the former U.S. brand name for molindone hydrochloride, a first-generation antipsychotic approved for schizophrenia. Its commercial lifecycle has ended as a branded product. The active ingredient has no meaningful remaining U.S. exclusivity, no significant publicly reported brand revenue, and limited commercial relevance compared with generic atypical antipsychotics such as risperidone, olanzapine, quetiapine, and aripiprazole. The primary market issue is supply continuity, not patent protection.
What is MOBAN and who marketed molindone?
MOBAN contained molindone hydrochloride, a dopamine D2-receptor antagonist in the dihydroindolone class. The FDA approved molindone in the 1970s for the management of schizophrenia. The product was administered orally in tablet strengths that included 5 mg, 10 mg, and 25 mg formulations.[1]
The original commercial product was marketed in the United States by Endo Pharmaceuticals and its predecessors. MOBAN was later discontinued as a branded product. The discontinuation was commercial rather than the result of an FDA finding that molindone was unsafe or ineffective.[2]
| Product |
Active ingredient |
Dosage form |
Primary indication |
Current commercial position |
| MOBAN |
Molindone hydrochloride |
Immediate-release tablet |
Schizophrenia |
Brand discontinued |
| Generic molindone |
Molindone hydrochloride |
Tablet |
Schizophrenia |
Limited and intermittent availability |
| Risperdal |
Risperidone |
Tablet, liquid, orally disintegrating tablet |
Schizophrenia and other indications |
Generic competition |
| Zyprexa |
Olanzapine |
Tablet, orally disintegrating tablet, injectable |
Schizophrenia and bipolar disorder |
Generic competition |
| Seroquel |
Quetiapine |
Immediate- and extended-release tablets |
Schizophrenia, bipolar disorder, depression adjunct |
Generic competition |
| Abilify |
Aripiprazole |
Tablet, liquid, injectable |
Schizophrenia and other indications |
Generic competition |
When did MOBAN lose exclusivity?
MOBAN lost meaningful U.S. market exclusivity decades ago. The original FDA approval dates to the 1970s, and any conventional composition-of-matter or formulation protection associated with the product would have expired long before the brand’s commercial discontinuation.
The modern product therefore has no viable exclusivity-based pricing model. Its commercial economics are determined by generic manufacturing costs, supplier participation, pharmacy purchasing policies, shortage conditions, and clinical demand.
MOBAN exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| FDA approval of molindone |
1970s |
Initial branded market entry |
| Generic competition |
Subsequent decades |
Price erosion and loss of branded protection |
| Branded MOBAN discontinuation |
Around 2010 |
End of the principal branded business |
| Current period |
2020s |
Limited generic and institutional relevance |
The FDA’s Orange Book does not provide a current patent-based barrier comparable to those associated with newer branded antipsychotics.[3]
What is the Orange Book status of MOBAN?
MOBAN is listed as a discontinued product associated with molindone hydrochloride. The Orange Book’s discontinued-drug status does not mean the active ingredient is prohibited. It indicates that the branded product is no longer marketed under its original approval status.
No active Orange Book patent estate is understood to protect MOBAN’s historical tablet formulation. The product has no meaningful remaining regulatory exclusivity, pediatric exclusivity, orphan exclusivity, or new-chemical-entity exclusivity.
| Orange Book issue |
MOBAN position |
| Listed active ingredient |
Molindone hydrochloride |
| Brand status |
Discontinued |
| Current patent barrier |
None of commercial significance |
| Regulatory exclusivity |
Expired |
| Paragraph IV relevance |
Low |
| Authorized generic risk |
Not commercially material |
| Generic substitution |
Dependent on current supply and state pharmacy rules |
What patents protect MOBAN and molindone?
No commercially relevant active patent estate protects the historical MOBAN product. The relevant protection categories are:
- The original molindone compound patent, which expired many years ago.
- Historical tablet-formulation and manufacturing claims, if any, which also would have expired.
- Potential process or formulation patents associated with later generic products, none of which creates meaningful market exclusivity for the active ingredient as a whole.
There is no evident patent position comparable to a modern branded antipsychotic protected by multiple formulation, delivery, method-of-use, and manufacturing patents.
Are there formulation patents for MOBAN?
The marketed MOBAN product was an immediate-release oral tablet. It did not establish a durable reformulation franchise, long-acting injectable platform, transdermal system, or extended-release product line.
That limits the ability to extend market exclusivity through lifecycle management. A company seeking to revive molindone commercially would need to rely on:
- A new dosage form;
- A differentiated delivery system;
- A clinically supported new indication;
- A combination product;
- A manufacturing-cost advantage; or
- A narrow institutional market with supply reliability.
A new formulation could receive patent protection if it met novelty, non-obviousness, and other U.S. patentability standards. That would protect only the claimed formulation or use, not the underlying molindone molecule.
Are there Paragraph IV challenges involving MOBAN?
Paragraph IV litigation has little practical relevance to MOBAN because the historical brand has no meaningful patent barrier. Generic applicants typically use an Abbreviated New Drug Application pathway when a reference product and regulatory framework support approval. Where no active Orange Book patent remains, an applicant does not face the same patent-certification risk associated with a protected branded drug.
No significant current Paragraph IV dispute is associated with the historical MOBAN franchise in the public record. The commercial risk is instead whether a manufacturer can maintain FDA-compliant production and whether enough demand exists to justify continued supply.
What is the FDA regulatory status of molindone?
Molindone was approved for schizophrenia. Its regulatory profile is that of an older conventional antipsychotic with a narrower modern commercial role.
The active ingredient is associated with class risks applicable to antipsychotic drugs, including extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, metabolic effects, and cardiovascular concerns. The product label also reflects the historical regulatory framework for conventional antipsychotics.[1]
Molindone does not have the broad indication portfolio that supports the larger revenues of newer antipsychotics. It lacks major branded indications in bipolar disorder, adjunctive depression, autism-related irritability, or long-acting maintenance therapy.
How strong is the MOBAN patent estate?
The MOBAN patent estate is commercially weak because it is effectively expired and lacks product differentiation.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Active Orange Book patents |
None of material commercial effect |
| Formulation protection |
No meaningful current barrier identified |
| Method-of-use protection |
No meaningful current barrier identified |
| Manufacturing protection |
Potentially relevant to cost, not market exclusivity |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Minimal |
| Ability to block generic entry |
None of practical significance |
The product could still have manufacturing know-how value, including process controls, impurity specifications, stability data, and validated analytical methods. Those assets may reduce production risk but do not prevent competitors from developing their own compliant processes.
What is the financial trajectory of MOBAN?
MOBAN’s financial trajectory is a decline from a branded prescription product to a low-volume or intermittent generic opportunity. Public company filings do not generally report molindone revenue as a separate line item. The product’s contribution was therefore not material enough to be consistently disclosed after the broader antipsychotic market became generic.
Historical revenue profile
The brand’s revenue likely followed four stages:
| Stage |
Market condition |
Financial effect |
| Branded launch |
Limited competition and physician familiarity |
Higher unit pricing |
| Mature brand |
Increasing therapeutic competition |
Volume and pricing pressure |
| Generic transition |
Multiple low-cost alternatives |
Rapid price erosion |
| Post-brand discontinuation |
Limited supply and niche use |
Low, volatile revenue |
The largest financial decline occurred after generic alternatives and newer atypical antipsychotics displaced conventional antipsychotics in prescribing. Brand discontinuation removed the ability to capture premium pricing, while low patient volume limited the attractiveness of generic production.
What market dynamics affect generic molindone?
Generic molindone operates in a small, price-sensitive market. Its principal commercial drivers are supply continuity and institutional demand.
Demand drivers
Demand is supported by:
- Patients who respond to molindone after inadequate response or intolerance to other antipsychotics;
- Prescribers seeking a conventional antipsychotic with a historical treatment record;
- Correctional, hospital, and public-sector formularies;
- Patients stabilized on molindone who face clinical risk from switching.
Demand is constrained by:
- Broad generic availability of newer antipsychotics;
- Limited contemporary clinical development;
- Few active promotional programs;
- Lack of long-acting injectable or extended-release options;
- Prescriber preference for drugs with larger modern evidence bases.
Supply drivers
Supply economics are more important than patent economics. A manufacturer must maintain:
- FDA-compliant active pharmaceutical ingredient sourcing;
- Validated tablet production;
- Adequate quality-control capacity;
- Stable demand sufficient to support batch sizes;
- Reliable distribution to wholesalers and institutional buyers.
For an older drug with limited demand, a single manufacturer’s production interruption can create disproportionate market disruption. That can produce temporary price increases without creating durable commercial value.
What generic launch risks exist for molindone?
A new generic entrant would face low patent risk but meaningful commercial risk.
| Risk |
Impact |
| Small addressable patient population |
Limits annual volume |
| Generic price competition |
Compresses gross margin |
| Low pharmacy inventory turnover |
Raises distribution costs |
| FDA manufacturing requirements |
Increases fixed costs |
| API sourcing concentration |
Creates supply vulnerability |
| Limited prescriber demand |
Slows market penetration |
| Reimbursement substitution |
Reduces net price |
| Product discontinuation by competitors |
Can create shortages but not sustained demand |
The most plausible launch model would be a low-overhead supply strategy focused on institutional buyers, specialty wholesalers, and continuity-of-care demand rather than a broad retail promotion campaign.
Which companies are challenging MOBAN’s market position?
No company needs to challenge MOBAN through patent litigation. Its competitive pressure comes from therapeutic substitutes and generic antipsychotics.
Principal competitors
Risperidone, olanzapine, quetiapine, and aripiprazole compete directly for schizophrenia prescriptions. Haloperidol and fluphenazine compete within the conventional-antipsychotic segment. Long-acting injectable products have an additional advantage in adherence management, a feature MOBAN does not offer.
The competitive landscape is therefore based on clinical utility, tolerability, dosage convenience, formulary position, and supply reliability rather than patent exclusivity.
What litigation and settlement agreements affect MOBAN?
No material current patent litigation or settlement agreement is associated with the historical MOBAN franchise. The absence of litigation reflects the lack of an active patent estate and the product’s limited commercial value.
Potential legal exposure would more likely involve:
- Product liability;
- Labeling and pharmacovigilance;
- Manufacturing compliance;
- Drug-shortage reporting;
- Distribution and substitution disputes.
Those issues differ from the patent litigation and Paragraph IV settlements that govern newer branded medicines.
What is the geographic coverage of MOBAN?
MOBAN’s principal commercial history is in the United States. Molindone may have had limited availability or historical use in other markets, but its international footprint is materially smaller than that of major global antipsychotic products.
Geographic commercial potential is limited by:
- Country-specific registration requirements;
- Local generic competition;
- Reimbursement restrictions;
- Small clinical demand;
- National procurement practices;
- Availability of alternative antipsychotics.
A multinational relaunch would require more than patent ownership. It would require country-level registrations, validated supply chains, and a clear clinical or economic reason for formulary adoption.
How does MOBAN compare with newer antipsychotics?
| Attribute |
MOBAN |
Newer atypical antipsychotics |
| Patent protection |
Expired |
Often expired or partially protected |
| Dosage options |
Primarily immediate-release tablets |
Tablets, liquids, injectables, extended-release products |
| Indication breadth |
Narrower |
Often broader |
| Brand pricing power |
None |
Depends on remaining exclusivity |
| Clinical evidence base |
Older |
More extensive contemporary development |
| Commercial promotion |
Minimal |
Historically substantial |
| Generic competition |
Established or intermittent |
Increasingly established |
| Long-acting option |
No |
Available for several competitors |
| Revenue potential |
Low |
Higher for differentiated products |
MOBAN’s commercial weakness is structural. A new owner would not acquire a conventional branded growth asset. It would acquire an old active ingredient with potential value in supply continuity, niche prescribing, or product redevelopment.
Key Takeaways
- MOBAN is the discontinued U.S. brand for molindone hydrochloride.
- FDA approval dates to the 1970s, and meaningful regulatory and patent exclusivity has expired.
- The Orange Book does not present a commercially significant active patent barrier.
- Paragraph IV litigation, patent settlements, and biosimilar risk are not material to the product.
- Biosimilar competition does not apply because molindone is a small-molecule drug, not a biologic.
- Brand revenue is no longer a meaningful commercial metric, and public filings do not generally disclose molindone sales separately.
- Generic economics depend on supply continuity, manufacturing cost, and institutional demand.
- The main competitive threat comes from generic atypical antipsychotics and long-acting injectable therapies.
- A commercial relaunch would require product differentiation, reliable manufacturing, or a focused institutional strategy.
- The financial outlook is low-volume and volatile rather than growth-oriented.
FAQs about MOBAN and molindone
Is MOBAN still available in the United States?
The original MOBAN brand is discontinued. Generic molindone availability has been limited and may vary by manufacturer, wholesaler, and pharmacy.
Does MOBAN have an active U.S. patent?
No commercially meaningful active U.S. patent barrier is associated with the historical MOBAN product.
Is molindone a biologic or biosimilar product?
No. Molindone is a chemically synthesized small-molecule drug. Biosimilar rules do not apply.
Could a company relaunch MOBAN?
A relaunch is legally possible through an approved product or generic pathway, but the commercial case is weak without a differentiated formulation, reliable supply advantage, or targeted institutional demand.
Why did MOBAN lose market share?
Molindone faced generic price erosion, limited modern product differentiation, and competition from atypical antipsychotics with broader indications, newer clinical data, and long-acting delivery options.
References
-
U.S. Food and Drug Administration. (n.d.). MOBAN (molindone hydrochloride) tablets prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Discontinued drugs and drug products. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-package
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
Endo Pharmaceuticals, Inc. (2010). Annual report and regulatory filings. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar.shtml
